Regarding those T2DM young patients at major risk of aggressive nephropathy, the study of a proper strategy to combine different hypoglycaemic drugs, alone or associated with insulin therapy, is of pivotal importance. The gene discussed is INS; the disease is type 2 diabetes mellitus.